Ameriprise Financial Inc. lessened its stake in Zogenix, Inc. (NASDAQ:ZGNX) by 64.3% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 73,897 shares of the company’s stock after selling 133,057 shares during the quarter. Ameriprise Financial Inc. owned 0.23% of Zogenix worth $2,590,000 at the end of the most recent quarter.
Other institutional investors and hedge funds also recently made changes to their positions in the company. SG Americas Securities LLC purchased a new position in shares of Zogenix in the 2nd quarter valued at about $100,000. Stifel Financial Corp purchased a new position in shares of Zogenix in the 2nd quarter valued at about $175,000. Voya Investment Management LLC increased its holdings in shares of Zogenix by 13.5% in the 2nd quarter. Voya Investment Management LLC now owns 14,147 shares of the company’s stock valued at $205,000 after purchasing an additional 1,686 shares in the last quarter. GSA Capital Partners LLP purchased a new position in shares of Zogenix in the 2nd quarter valued at about $231,000. Finally, Alliancebernstein L.P. increased its holdings in shares of Zogenix by 16.3% in the 2nd quarter. Alliancebernstein L.P. now owns 17,812 shares of the company’s stock valued at $258,000 after purchasing an additional 2,500 shares in the last quarter. Institutional investors and hedge funds own 73.43% of the company’s stock.
In other Zogenix news, Director Roger Hawley sold 11,797 shares of the firm’s stock in a transaction dated Friday, December 8th. The shares were sold at an average price of $37.02, for a total transaction of $436,724.94. Following the sale, the director now directly owns 105,575 shares of the company’s stock, valued at approximately $3,908,386.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Bradley S. Galer purchased 1,346 shares of the firm’s stock in a transaction on Wednesday, December 13th. The shares were purchased at an average cost of $36.59 per share, for a total transaction of $49,250.14. The disclosure for this purchase can be found here. 5.00% of the stock is currently owned by corporate insiders.
Shares of Zogenix, Inc. (ZGNX) opened at $34.60 on Friday. The company has a market cap of $1,090.00, a PE ratio of -7.88 and a beta of 1.96. Zogenix, Inc. has a 12 month low of $7.70 and a 12 month high of $43.35. The company has a quick ratio of 2.71, a current ratio of 2.71 and a debt-to-equity ratio of 0.23.
ILLEGAL ACTIVITY NOTICE: This report was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this report on another site, it was copied illegally and reposted in violation of international trademark and copyright law. The correct version of this report can be read at https://www.com-unik.info/2018/01/06/zogenix-inc-zgnx-shares-sold-by-ameriprise-financial-inc.html.
Zogenix, Inc is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome.
What are top analysts saying about Zogenix? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Zogenix and related companies.